- Home
- FRPT vs KNSA Comparison
FRPT vs KNSA Comparison
Compare FRPT & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRPT
- KNSA
- Stock Information
- Founded
- FRPT 2004
- KNSA 2015
- Country
- FRPT United States
- KNSA United Kingdom
- Employees
- FRPT N/A
- KNSA N/A
- Industry
- FRPT Packaged Foods
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- FRPT Consumer Staples
- KNSA Health Care
- Exchange
- FRPT Nasdaq
- KNSA Nasdaq
- Market Cap
- FRPT 3.1B
- KNSA 2.6B
- IPO Year
- FRPT 2014
- KNSA 2018
- Fundamental
- Price
- FRPT $53.50
- KNSA $38.49
- Analyst Decision
- FRPT Buy
- KNSA Strong Buy
- Analyst Count
- FRPT 16
- KNSA 7
- Target Price
- FRPT $117.27
- KNSA $44.00
- AVG Volume (30 Days)
- FRPT 1.6M
- KNSA 436.7K
- Earning Date
- FRPT 11-03-2025
- KNSA 10-28-2025
- Dividend Yield
- FRPT N/A
- KNSA N/A
- EPS Growth
- FRPT 28.97
- KNSA N/A
- EPS
- FRPT 0.66
- KNSA 0.07
- Revenue
- FRPT $1,044,013,000.00
- KNSA $529,332,000.00
- Revenue This Year
- FRPT $16.18
- KNSA $37.21
- Revenue Next Year
- FRPT $12.89
- KNSA $11.99
- P/E Ratio
- FRPT $81.06
- KNSA $595.49
- Revenue Growth
- FRPT 19.30
- KNSA 56.18
- 52 Week Low
- FRPT $48.41
- KNSA $17.82
- 52 Week High
- FRPT $164.07
- KNSA $39.12
- Technical
- Relative Strength Index (RSI)
- FRPT 47.32
- KNSA 64.11
- Support Level
- FRPT $52.29
- KNSA $37.35
- Resistance Level
- FRPT $56.01
- KNSA $39.12
- Average True Range (ATR)
- FRPT 2.00
- KNSA 0.99
- MACD
- FRPT 0.74
- KNSA 0.08
- Stochastic Oscillator
- FRPT 66.97
- KNSA 83.55
About FRPT Freshpet Inc.
Freshpet produces and sells premium fresh pet food through its company-owned refrigerators placed in grocery, mass and club, pet specialty, and natural stores. Freshpet primarily targets dogs (96% of 2024 sales), with cats and treats comprising the rest of its sales. Geographically, the company's home US market, where all its food is produced, accounts for about 98% of sales, with exports to Canada, the United Kingdom, and other European countries accounting for the remaining balance.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.